Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Prevalence and Impact of the KIT M541L Variant in Patients With Mastocytosis

News

July 24, 2024
PRESS RELEASE: On July 22, 2024, a new research paper was published in Oncotarget, entitled, “Prevalence and impact of the KIT M541L variant in patients with mastocytosis.” continue reading »

Oncotarget Welcomes New Editorial Board Members

News

July 22, 2024
Oncotarget is also offering a 50% discount on publication fees until the end of the year. continue reading »

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

News

July 22, 2024
PRESS RELEASE: On July 10, 2024, a new research paper was published in Oncotarget, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.” continue reading »

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

News

July 19, 2024
PRESS RELEASE: On July 2, 2024, a new editorial was published in Oncotarget, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.” continue reading »

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

News

July 17, 2024
PRESS RELEASE: On July 2, 2024, a new editorial was published in Oncotarget, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.” continue reading »